Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Stryker is enjoying strong demand for its MAKO robotic surgery platform with plans to increase system placements and procedure volumes while working on a next-gen system that would enhance ease-of-use for surgeons and improve accuracy. The company also has plans to expand into other areas of focus, according to analyst reports from this year's AAOS annual meeting in New Orleans. Meanwhile, Smith & Nephew and Zimmer Biomet are trying to set themselves apart with their robotic technologies.
Latest From Clinical Trials
US FDA is working with manufacturers, researchers and other stakeholders to assemble a comprehensive network of registries of cardiac device data. But cardiologists and device firms say the project faces multiple challenges.
Stryker's Trevo Retriever is the first stent retriever approved by US FDA as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, matching the time window recommended in the latest professional treatment guidelines. Now, the company is trying to help the stroke-care system in the US catch up to the science.
Starts & Stops is a regular feature in Medtech Insight highlighting noteworthy clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers the trial announcements between Mar. 5-11, 2018, including clinical trial announcements from Mercator MedSystems, Boston Scientific and Brainsway Ltd.
The late-breaking trials presented at the 2018 CRT Conference in Washington, DC, March 3-6 included new clinical data on novel drug-eluting coronary stents, endovascular peripheral vascular interventions, and transcatheter heart valve devices, plus a major trial comparing transfemoral and transradial coronary interventions.
Point-by-point clinical trial recommendations from US FDA's Neurological Devices Advisory Panel at a recent meeting on intracranial aneurysm devices.
Check out what US FDA Neurological Devices Panel Chair Mary Jensen had to say about the biggest point of debate at a recent panel meeting that focused on clinical trial requirements for intracranial aneurysm devices.
To help figure out how intracranial aneurysm devices should be evaluated in clinical trials, US FDA brought together its Neurological Devices Advisory Panel. The experts answered questions ranging from safety and efficacy endpoints that should be taken into consideration to post-market study requirements.
In this edition of the Device Week podcast, Medtech Insight’s Reed Miller and Marion Webb discuss medtech’s role in combatting rheumatoid arthritis and they highlight some recent clinical trial initiations and completions.
Starts & Stops is a regular feature in Medtech Insight highlighting noteworthy clinical trial announcements, initiations, completions, and suspensions tracked by Meddevicetracker. This edition covers the start of 2018, which includes important trial announcements from Abbott, Boston Scientific, Medtronic, Edwards and many more. The Stops & Starts feature will be switching to a weekly schedule as of March 5 to offer more timely updates on medical device trials.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.